Clinical Calculators

Ascites SAAG & SBP Diagnostic Assistant

Enter an ascitic fluid panel and see what the AASLD and EASL guidelines make of it: the serum-ascites albumin gradient against the 1.1 g/dL portal-hypertension cut-off, the total protein, spontaneous bacterial peritonitis by neutrophil count, and the secondary-peritonitis criteria — each with the guideline name and year beside it, and with the places the two societies disagree shown rather than reconciled.

1 · Ascitic fluid panel
Albumin & protein units
AASLD 2021: the gradient is the serum albumin minus the ascitic fluid albumin in simultaneously obtained samples.
Absolute polymorphonuclear count, not the total white cell count.
2 · Secondary peritonitis panel  (optional)
Glucose units
The criterion is “greater than the upper limit of normal for serum”, which is assay- and laboratory-specific. No default is supplied because no guideline states one.
3 · Follow-up & prophylaxis  (optional)
Worked examples
Illustrative laboratory patterns for exploring how the thresholds behave. They are not case reports and describe no real patient.
Assessment
Serum-ascites albumin gradient
Ascitic fluid infection
Secondary bacterial peritonitis
Response to empirical antibiotics at 48 hours
Primary SBP prophylaxis — both criteria sets, unmerged
Guideline reference — quoted, not summarised
Management of SBP

Empirical antibiotics, community-acquired SBP AASLD 2021

IV third-generation cephalosporin is first line where multidrug-resistant organisms are not prevalent; AASLD 2021 gives IV cefotaxime 2 g every 12 hours as its worked example.

“Currently, they are recommended as the first-line antibiotics (e.g., IV cefotaxime 2 g every 12 hours) in settings where MDROs are not prevalent.”

Empirical antibiotics, nosocomial or health-care-associated SBP AASLD 2021

Broader first-line cover; AASLD 2021 Table 9 lists piperacillin/tazobactam AND daptomycin (if known VRE or GI colonisation) OR meropenem if known to harbour MDR gram-negative organisms.

“In patients with a health care-associated or nosocomial infection or recent exposure to broad-spectrum antibiotics or who are admitted with sepsis or septic shock, empirical therapy with broad-spectrum antibiotics should be initiated as the first line.”

Duration of antibiotic therapy AASLD 2021

AASLD 2021: 5-7 days. EASL 2018: at least 5-7 days (III;1).

“The recommended duration of antibiotic therapy is 5-7 days.”

IV albumin in SBP AASLD 2021

1.5 g/kg on day 1 and 1 g/kg on day 3, in addition to antibiotics.

“Patients with SBP should be treated with IV albumin in addition to antibiotics (1.5 g/kg at day 1 and 1 g/kg at day 3). Patients with AKI and/or jaundice at time of diagnosis of SBP are more likely to benefit from albumin.”

EASL 2018 (I;1): The administration of albumin (1.5 g/kg at diagnosis and 1 g/kg on day 3) is recommended in patients with SBP.

Bacterascites without signs of infection AASLD 2021

AASLD 2021 says do not give antibiotics and repeat the paracentesis; EASL 2018 says treat if there are signs of systemic inflammation, otherwise repeat – see ‘disagreements’.

“Patients with ascites PMN <250/mm3 and a positive bacteriological culture (bacterascites) in the absence of any signs of infection should not receive antibiotics, as in most cases it self-resolves or is a contaminant. A repeat diagnostic paracentesis should be performed to investigate progression to SBP.”

Non-selective beta-blockers during SBP AASLD 2021

Hold temporarily if hypotensive or with AKI.

“NSBBs should be temporarily held in patients with SBP who develop hypotension (mean arterial pressure <65 mm Hg) or AKI.”

Secondary SBP prophylaxis (after a first episode) AASLD 2021

Long-term daily norfloxacin; oral ciprofloxacin 500 mg/day is acceptable where norfloxacin is unavailable.

“Patients who have recovered from an episode of SBP should receive long-term prophylaxis with daily norfloxacin. In settings in which norfloxacin is unavailable, oral ciprofloxacin is acceptable.”

EASL 2018 records norfloxacin 400 mg/day orally as the only regimen tested in a randomised double-blind placebo-controlled trial in this population.

Prophylaxis during acute upper GI haemorrhage AASLD 2021

IV ceftriaxone 1 g every 24 hours, for a maximum of 7 days.

“Antibiotic prophylaxis for SBP should be instituted in patients with cirrhosis and upper gastrointestinal hemorrhage. IV ceftriaxone 1 g/24 hours is the antibiotic of choice and should be used for a maximum of 7 days.”

Primary SBP prophylaxis in low-protein ascites AASLD 2021

Considered only in selected patients who also have renal dysfunction or advanced liver failure – see ‘prophylaxis’.

“In patients with cirrhosis and low protein (<1.5 g/L) ascites, primary SBP prophylaxis can be considered in selected patients with renal dysfunction (serum creatinine level >1.2 mg/dL, blood urea nitrogen level >25 mg/dL, or serum sodium level <130 mEq/L) or liver failure (Child-Turcotte-Pugh score >9 and bilirubin >3 mg/dL).”

Diuretic reference (not a dosing calculator)
This is a reference table, not a dosing calculator
Shown for reference only because the ratio was explicitly asked for. This tool does not compute, suggest or titrate a dose for any individual. Every figure below is quoted from the document named beside it.

Spironolactone : furosemide ratio — 100 mg : 40 mg (spironolactone : furosemide) AASLD 2009

“The doses of both oral diuretics can be increased simultaneously every 3-5 days (maintaining the 100 mg:40 mg ratio) if weight loss and natriuresis are inadequate. In general, this ratio maintains normokalemia. Usual maximum doses are 400 mg/day of spironolactone and 160 mg/day of furosemide.”

Read this caveat before using the ratio. This ratio is stated in the SUPERSEDED AASLD 2009 guideline. The current AASLD 2021 guidance does NOT restate a fixed ratio – it gives starting and maximum doses for each drug separately. EASL 2018 and EASL 2010 also state no ratio, and EASL 2018 explicitly says loop diuretics ‘should be combined with but not substituted for anti-mineralocorticoids’. It is included here only because it is a named-guideline figure; it is not a current AASLD or EASL recommendation.

ItemValue as publishedSource and exact wording
Spironolactone, starting dose100 mg/dayAASLD 2021
“The recommended initial dose of spironolactone is 100 mg/day, which can be progressively increased up to 400 mg/day.”
Spironolactone, maximum400 mg/dayAASLD 2021
“which can be progressively increased up to 400 mg/day”
EASL 2018 (I;1) and EASL 2010 (A1) both give 400 mg/day as the maximum, in 100 mg steps.
Spironolactone, minimum interval between dose increasesat least 72 hours (AASLD 2021, EASL 2018) / every 7 days (EASL 2010)AASLD 2021
“When the dose is increased, it should be done cautiously and in a stepwise fashion, with an interval of at least 72 hours.”
Differs: EASL 2010 (A1) specifies ‘increasing stepwise every 7 days (in 100 mg steps)’. EASL 2018 (I;1) revised this to ‘stepwise increases every 72 h (in 100 mg steps)’, which agrees with AASLD 2021.
Furosemide, starting dose40 mg/dayAASLD 2021
“The dose of furosemide (initially 40 mg/day) may be progressively increased, according to the response and tolerability toward 160 mg/day”
EASL 2018 (I;1): added at an increasing stepwise dose from 40 mg/day, in 40 mg steps.
Furosemide, maximum160 mg/dayAASLD 2021
“toward 160 mg/day, which is the generally accepted threshold to determine medical treatment refractoriness”
EASL 2018 (I;1) and EASL 2010 (A1) both give 160 mg/day.
Maximum weight loss, no peripheral oedema0.5 kg/dayAASLD 2021
“in a patient without peripheral edema, weight loss exceeding 0.5 kg per day may result in plasma volume contraction, predisposing the patient to renal failure and hyponatremia”
EASL 2010 (A1) and EASL 2018 both give 0.5 kg/day without oedema.
Maximum weight loss, with peripheral oedema1 kg/dayAASLD 2021
“In those with edema, weight loss up to 1 kg/day may be tolerated.”
EASL 2010 (A1) and EASL 2018 both give 1 kg/day with oedema.
Dietary sodium restriction2 g (90 mmol) sodium per dayAASLD 2021
“Moderate sodium restriction (2 g or 90 mmol/day) and diuretics (spironolactone with or without furosemide) are the first-line treatment in patients with cirrhosis and grade 2 ascites.”
Differs: EASL 2010 (B1) recommends a less restrictive 80-120 mmol/day, ‘which corresponds to 4.6-6.9 g of salt/day’.
Where the societies disagree

Ascitic glucose and LDH for diagnosing secondary bacterial peritonitis

AASLD 2009 Endorses the criteria
At least two of total protein >1 g/dL, LDH above the serum upper limit of normal, and glucose <50 mg/dL, in a patient with PMN >=250 cells/mm3. Reported as 100% sensitive but only 45% specific for free perforation, and only 50% sensitive for non-perforation secondary peritonitis.
“It is useful to order an ascitic fluid Gram stain, culture, total protein, LDH, and glucose in patients with cirrhosis and ascites and an ascitic fluid PMN count >=250 cells/mm3.”

EASL 2010 Recommends against B1
EASL 2010 issues an explicit graded recommendation not to use these tests for this purpose, on the grounds that the sensitivity and specificity data in this setting are very limited.
“The use of other tests such as measurement of glucose or lactate dehydrogenase in ascitic fluid cannot be recommended for the diagnosis of secondary bacterial peritonitis (Level B1).”

EASL 2018 Omits them entirely III;1
EASL 2018 drops glucose and LDH from its secondary-peritonitis recommendation altogether and routes suspicion to imaging and surgery instead.
“Patients with suspected secondary bacterial peritonitis should undergo prompt CT scanning and early considerations for surgery (III,1).”

How this tool handles it. This tool computes the Runyon criteria when you supply the values, labels the panel with AASLD 2009 and its performance figures, and prints the EASL position beside the result every time. It does not average the two, does not hide either, and does not present a Runyon-positive result as a diagnosis.

Bacterascites without signs of infection

AASLD 2021 Do not treat; repeat the tap
“Patients with ascites PMN <250/mm3 and a positive bacteriological culture (bacterascites) in the absence of any signs of infection should not receive antibiotics, as in most cases it self-resolves or is a contaminant. A repeat diagnostic paracentesis should be performed to investigate progression to SBP.”

EASL 2018 Repeat the tap, and treat on a second positive culture regardless of the neutrophil count II-2;1 / III;1
“Otherwise, the patient should undergo a second paracentesis. If the culture results come back positive again, regardless of the neutrophil count, the patient should be treated (III;1).”

How this tool handles it. Both are shown whenever the tool classifies a sample as bacterascites.

Which patients with SBP benefit most from IV albumin

AASLD 2021 BUN >30 mg/dL or creatinine >1.0 mg/dL, or bilirubin >5 mg/dL
“patients who most benefited from albumin were those who already had evidence of renal dysfunction (blood urea nitrogen >30 mg/dL or creatinine >1.0 mg/dL) or severe hepatic decompensation (bilirubin >5 mg/dL)”

EASL 2018 Bilirubin >=4 mg/dL or serum creatinine >=1 mg/dL
“Treatment with albumin was particularly effective in patients with baseline serum bilirubin >=68 lmol/L (4 mg/dl) or SCr >=88 lmol/L (1 mg/dl).”

AASLD 2009 Creatinine >1 mg/dL, BUN >30 mg/dL, or total bilirubin >4 mg/dL
“creatinine >1 mg/dL, blood urea nitrogen >=30 mg/dL, or total bilirubin >=4 mg/dL”

How this tool handles it. The bilirubin threshold differs between the two current documents (5 mg/dL vs 4 mg/dL). Both are printed, attributed, and neither is averaged. The albumin DOSE (1.5 g/kg then 1 g/kg) is identical in both and is not in dispute. This tool does not take a bilirubin or creatinine input and does not decide whether to give albumin.

Ascitic protein threshold for SBP risk – printed units

AASLD 2021 Narrative says <1.5 g/dL; the Guidance Statement prints <1.5 g/L
“low (<1.5 g/dL) ascitic fluid protein concentration predisposes to the development of SBP / In patients with cirrhosis and low protein (<1.5 g/L) ascites”

EASL 2018 <15 g/L, i.e. 1.5 g/dL I;1
“ascitic fluid protein lower than 15 g/L”

How this tool handles it. 1.5 g/L would be one tenth of every other published value. This tool uses 1.5 g/dL = 15 g/L, which is what EASL 2018, EASL 2010 and the AASLD 2021 narrative all state, and shows this note rather than quietly choosing.

Methodology, sources & what this tool leaves out
Sources — all four read as published full text
  • AASLD 2021 Biggins SW, Angeli P, Garcia-Tsao G, Gines P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048. doi:10.1002/hep.31884
    Status: current
    Grading: AASLD Practice Guidance documents carry no formal per-statement grade; they are consensus Guidance Statements rather than graded Guidelines.
  • EASL 2018 European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024
    Status: current
    Grading: Graded as (evidence level; strength of recommendation), e.g. (II-2;1) or (I;1).
  • EASL 2010 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53(3):397-417. doi:10.1016/j.jhep.2010.05.004
    Status: largely superseded by EASL 2018, retained here because it is the only one of the four documents that issues an explicit graded recommendation against ascitic glucose and LDH for diagnosing secondary bacterial peritonitis
    Grading: GRADE: evidence A (high) / B (moderate) / C (low); recommendation 1 (strong) / 2 (weak).
  • AASLD 2009 Runyon BA. Management of Adult Patients with Ascites Due to Cirrhosis: An Update. AASLD Practice Guideline. Hepatology 2009;49(6):2087-2107. doi:10.1002/hep.22853
    Status: SUPERSEDED by AASLD 2021. Used in this tool only for the two items the 2021 guidance does not restate: the secondary-peritonitis (Runyon) criteria and the 100 mg : 40 mg spironolactone-to-furosemide ratio. Every screen that shows one of those items says so.
    Grading: Class I/II/III with Level A/B/C.

Four primary guideline documents, each read directly as published full text (PDF) on 2026-08-01, not from secondary summaries or review articles: (1) Biggins SW, Angeli P, Garcia-Tsao G, Gines P, Ling SC, Nadim MK, Wong F, Kim WR. ‘Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.’ Hepatology 2021;74(2):1014-1048 – Tables 2, 3, 4, 5 and 9 and the narrative plus Guidance Statements of the ascites, SBP, albumin and prophylaxis sections. (2) European Association for the Study of the Liver. ‘EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.’ J Hepatol 2018;69(2):406-460 – the ascites diagnosis, diuretic, SBP diagnosis, SBP management, albumin and SBP prophylaxis Recommendation boxes with their evidence/strength grades. (3) European Association for the Study of the Liver. ‘EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.’ J Hepatol 2010;53(3):397-417 – sections 1.2, 1.4.2.2, 3.1.5 and 3.2 Recommendation boxes with GRADE levels. (4) Runyon BA. ‘Management of Adult Patients with Ascites Due to Cirrhosis: An Update.’ AASLD Practice Guideline, Hepatology 2009;49(6):2087-2107 – the ascitic fluid analysis, ‘Distinction from Secondary Bacterial Peritonitis’ and diuretic sections. Document (4) has been superseded by document (1) and is used here only for the two items that document (1) does not restate: the Runyon secondary-peritonitis criteria and the 100 mg : 40 mg diuretic ratio; both are labelled as such wherever they appear.

Data file built 2026-08-01 · scheduled re-verification 2027-02-01

Sourcing rule

No threshold, cut-off, dose, accuracy figure or differential-diagnosis entry appears in this file unless it was read off one of the four primary documents named in _source, and every row carries the document it came from and that document’s year. Nothing is averaged, interpolated, rounded to a nicer number, or carried across from a similar guideline. Where the four documents genuinely disagree, both positions are stored side by side under ‘disagreements’ with their own attribution rather than reconciled. Items that could not be sourced from any of the four documents were left out entirely and are listed under ‘omitted’ with the reason – most importantly the red-blood-cell correction of the ascitic neutrophil count in a bloody tap, which none of the four documents states. Inequality wording is stored exactly as published (‘>250/mm3’ vs ‘>=250 cells/mm3’), and the boundary this tool actually applies is declared in ‘boundary_notes’.

How boundaries are handled
  • PMN cut-off wording. AASLD 2021, EASL 2018 and EASL 2010 all word the SBP threshold as ‘>250/mm3’; the superseded AASLD 2009 guideline words it as ‘>=250 cells/mm3’. Read literally, a count of exactly 250 is negative under the first wording and positive under the second. This tool treats exactly 250 cells/mm3 as MEETING the threshold, which is the more sensitive reading and is consistent with the reason AASLD 2021 gives for choosing 250 at all: ‘a cutoff with the highest sensitivity chosen to avoid SBP being untreated’. The tool says so on screen whenever the entered count is exactly 250.
  • SAAG cut-off. All four documents word this as ‘>=1.1 g/dL’, so a SAAG of exactly 1.1 g/dL reflects portal hypertension. No interpretation was needed.
  • SAAG rounding. The gradient is computed from your entries, then rounded to three decimal places before it is compared with the cut-off, and displayed to two. The rounding exists only to cancel binary floating-point error: without it, 3.5 – 2.4 evaluates to 1.0999999999999996 in JavaScript and a genuine SAAG of 1.1 g/dL would be misclassified as below the cut-off. Three decimals is finer than any albumin assay reports, so the rounding cannot move a real result across the boundary. A serum albumin of 3.55 with an ascitic albumin of 2.46 gives 1.09 and is correctly classified as below the cut-off.
  • Runyon protein criterion. AASLD 2009 words it as ‘total protein >1 g/dL’, so exactly 1.0 g/dL does NOT meet the criterion. Glucose is worded ‘<50 mg/dL’, so exactly 50 mg/dL does NOT meet it. LDH is worded ‘greater than the upper limit of normal for serum’, so an ascitic LDH exactly equal to your laboratory’s serum upper limit does NOT meet it. All three are implemented strictly as printed.
  • Cardiac-source protein criterion. AASLD 2021 words it ‘>2.5 g/dL’, so exactly 2.5 g/dL does not trigger the cardiac-source note.
  • Low-protein SBP-risk criterion. Worded ‘<1.5 g/dL’, so exactly 1.5 g/dL is not flagged.
Unit conversions
  • albumin / protein: g/dL ↔ g/L. 1 g/dL = 10 g/L exactly. This is a decimal unit change, not an assay conversion.
  • glucose: mg/dL ↔ mmol/L. mg/dL = mmol/L x 18.0182, from the molar mass of D-glucose, 180.156 g/mol (IUPAC standard atomic weights 2021, C6H12O6). The Runyon threshold of 50 mg/dL is therefore 2.775 mmol/L; the Gastroenterology 1990 abstract rounds it to 2.8 mM. The tool converts your entry with the exact factor and applies the threshold in mg/dL, the unit the guideline states.
Deliberately left out — because it could not be grounded
  • Red-blood-cell correction of the ascitic neutrophil count in a bloody or traumatic tap (the widely quoted ‘subtract 1 PMN per 250 RBC’)
    None of the four primary guideline documents read for this tool states this correction, or any numeric correction, or the RBC count at which a tap should be called bloody. AASLD 2021 does not mention red blood cells in the ascitic fluid at all. AASLD 2009 names haemorrhagic ascites only qualitatively, as one of several alternative explanations for a raised PMN count. Rather than import the figure from a textbook or a secondary summary, the correction is left out and the tool shows a qualitative caution instead.
  • Any predicted mortality, recurrence or event probability for a given SAAG, protein or PMN value
    None of the four documents publishes a probability table keyed to these values, so no risk figure could be grounded. Population-level figures that do appear in the documents (for example the roughly 20% in-hospital mortality of SBP) are properties of published cohorts, not of the numbers a user types in, and are not presented as an output of this calculator.
  • Reagent-strip / urine-dipstick rapid diagnosis of SBP
    EASL 2018 states ‘The use of reagent strips has no clear evidence to support it in routine practice (II-2;1)’ and EASL 2010 states there are insufficient data to recommend them. No usable threshold exists to implement, so this is left out.
  • Serum or ascitic BNP, ascitic cholesterol and ascitic fibronectin cut-offs
    AASLD 2021 and AASLD 2009 give no cut-off for BNP. EASL 2018 mentions an ascitic cholesterol figure of 45 mg/dl only as a trigger for ordering cytology and CEA in the malignancy work-up, not as a diagnostic threshold, and none of the other three documents corroborates it, so it is not implemented as a test.
  • Automated cell-counter and flow-cytometry equivalence factors
    EASL 2018 permits a flow-cytometry-based automated count as a substitute for microscopy but publishes no conversion, correction or equivalence factor, so none is applied. The tool takes whatever count your laboratory reports at face value.
  • Paediatric SBP thresholds
    The AASLD 2021 paediatric section reports SBP identified in 19% of children in a cited series using an ascites PMN count >250/mm3, but publishes no separate paediatric cut-off, and EASL 2018 and EASL 2010 address adults. This tool therefore states that it is an adult tool rather than implying the adult thresholds are validated in children.
  • A recommended empirical antibiotic for the individual patient
    Antibiotic choice in both current documents depends on local multidrug-resistance prevalence, prior exposure, colonisation status and severity – none of which this tool asks for and none of which it could responsibly infer. The guideline text is reproduced as a reference block only, and no regimen is selected for anyone.
Scope and limitations. Decision support for qualified clinicians. This tool reproduces published guideline thresholds and applies them to numbers you type in. It does not diagnose, does not triage, does not prescribe, and is not a substitute for clinical judgement, local protocol, microbiology or direct patient assessment. It is not for patient self-diagnosis or self-management. Nothing entered here is transmitted, stored or logged anywhere – all arithmetic happens in your own browser. This is an adult tool: the AASLD 2021 paediatric section reports SBP in children using the same >250/mm³ count but publishes no separate paediatric cut-off, and the EASL documents address adults. No figure on this page is an output of a model, a regression or an estimate — every number is a threshold, dose or accuracy figure printed in one of the four documents cited above, reproduced with its source and year attached.
Was this tool helpful?